-
New progress in the consistency evaluation of generic drugs! Last week, 5 pharmaceutical companies were the first to review
Time of Update: 2022-04-15
According to incomplete statistics, in the last week (March 20, 2022-March 26, 2022), 23 new varieties (deemed as) have been reviewed, of which 5 are the first review, namely Hengrui's gadolinium Butol injection, Hisco's arginine and glutamate injection, Chia Tai Tianqing's methacholine for inhalation, Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel, Chengji Pharmaceutical's cyproheptadine hydrochloride Oral solution .
-
Changes in executives of multinational pharmaceutical companies in April!
Time of Update: 2022-04-15
Not long ago, Zai Lab also announced that it appointed Josh Smiley, who was responsible for finance, corporate strategy, business development, venture capital and global business service operations at Eli Lilly, as chief operating officer, reporting directly to the CEO.
-
This week, a group of pharmaceutical companies have "changed coaches" one after another
Time of Update: 2022-04-15
On March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer .
On March 29, Hainan Haiyao issued an announcement showing that the board of directors received a written resignation application report from the chairman of the company, Mr.
-
The outbreak of anti-tumor drugs is imminent, and many pharmaceutical companies have several varieties under development
Time of Update: 2022-04-15
In the face of a considerable market blue ocean, in recent years, a large number of domestic and foreign pharmaceutical companies have been attacking the anti-tumor drug market, increasing investment in research and development, strengthening cooperation between companies, and enriching the company's product pipeline .
-
11 medical device companies disclosed their annual reports, and 3 companies’ net profit growth rate exceeded 100%
Time of Update: 2022-04-15
Leadman's 2021 annual report shows that during the reporting period, the company achieved operating income of 564 million yuan, a year-on-year increase of 19.
The company plans to distribute cash dividends of 22 yuan (tax included) for every 10 shares to all shareholders .
-
The average price of artificial joints has been reduced by more than 80%, and enterprises are expected to achieve "price-for-volume"
Time of Update: 2022-04-15
The "Selected Results of Centralized Procurement of Artificial Joints by the State Organization" included in the "Notice" shows that the hip joint products in this centralized procurement are divided into three groups according to ceramic-ceramic, ceramic-polyethylene, and alloy-polyethylene.
-
Another batch of pharmaceutical companies, layoffs!
Time of Update: 2022-04-15
Recently, another batch of pharmaceutical companies made layoff decisions: Biogen announced layoff-related matters to some employees in the United States; Dongpei Pharmaceuticals basically disbanded its sales team in China; Gilead plans to lay off 114 employees in Morris Plains, New Jersey.
-
For this variety of constipation treatment, many pharmaceutical companies have won bids to segment the market
Time of Update: 2022-04-15
On December 28, 2018, Watson Pharmaceuticals announced that the company's polyethylene glycol 4000 powder (specification: 10g) passed the consistency evaluation .
In the second batch of national centralized drug procurement, polyethylene glycol 4000 powder (10g) was won by 4 companies including Watson Pharmaceuticals .
-
With the continuous emergence of innovative achievements, pharmaceutical companies' innovative drug revenue growth rate is strong
Time of Update: 2022-04-15
It is worth mentioning that in the context of the continuous launch of innovative drugs, the growth rate of a large number of drug revenues is also very strong, which has brought benefits to many pharmaceutical companies .
-
Since March, a number of pharmaceutical equipment companies have received the attention of securities companies' research reports
Time of Update: 2022-04-15
Since March, a number of pharmaceutical equipment companies have received the attention of research reports from securities companies, including Chutian Technology, Tofflon, and Chengyitong .
-
109 listed pharmaceutical companies plan to distribute over 26.3 billion yuan, and the total dividends of this company far exceed the annual net profit
Time of Update: 2022-04-15
According to Zhendong Pharmaceutical's announcement on March 31, the company's 2021 profit distribution plan is: to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares, with a total cash dividend of more than 2.
-
The development of the medical industry continues to improve, and companies are setting off a wave of listings
Time of Update: 2022-04-15
According to the review results of the meeting, the MicroPort Electrophysiology Science and Technology Innovation Board has been approved for the first time .
The smooth passing of this electrophysiology meeting indicates that the domestic innovative medical device industry will usher in new development opportunities .
-
Within 1 day, a number of pharmaceutical companies were newly appointed as deputy general managers!
Time of Update: 2022-04-15
On March 24, news of the newly appointed deputy general manager came out from a number of pharmaceutical companies, including Haier Bio, Dorui Medicine, and Kangtuo Medical .
Shang Weiwei as the company's deputy general manager Kangtuo Medical Announcement, the company's board of directors agreed to appoint Ms.
-
The 15th "World Autism Day", the current situation of drug research and development attracts attention
Time of Update: 2022-04-15
In the United States, the current drugs for autism treatment, risperidone and aripiprazole, are antipsychotic drugs, not for core symptoms .
In 2006, the FDA approved Johnson & Johnson's risperidone for the treatment of irritability in children with autism from 5 to 16 years old.
-
good news!
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] Recently, Hainan Boao Lecheng International Medical Tourism Pilot Zone has successfully introduced the invasive fungal disease treatment drug-AmBisome (Amphotericin B liposome for injection), which will provide domestic invasive fungal diseases.
-
2022 first quarter performance forecasts have been disclosed one after another, a pharmaceutical company’s revenue and net profit have both surged
Time of Update: 2022-04-15
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period .
-
In the first quarter of 2022, companies in the field of biological products performed well
Time of Update: 2022-04-15
For example, Tonghua Dongbao, an "insulin leader", expects to achieve a net profit of 817 million yuan attributable to shareholders of listed companies in the first quarter of 2022, an increase of 480 million yuan over the same period last year, or an increase of about 142.
-
Under the normalization of centralized procurement, a large number of pharmaceutical companies have accelerated the consistency evaluation!
Time of Update: 2022-04-15
Tianyao announced on the evening of March 22 that the dexamethasone sodium phosphate injection of its subsidiary Jinyao Pharmaceutical passed the quality and efficacy consistency evaluation of generic drugs .
-
A large number of pharmaceutical companies continued to perform well in the first quarter, with a sharp increase in net profit
Time of Update: 2022-04-15
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period .
-
A large number of domestic pharmaceutical companies are speeding up to grab the market for original research drugs!
Time of Update: 2022-04-15
It is worth mentioning that, in addition to Nanjing Chia Tai Tianqing, there are more than 10 domestic pharmaceutical companies that have obtained clinical approval for ramelteon tablets.
